Abnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy.
BACKGROUND
Ca2+ is known to be involved in a number of metastatic processes including motility and proliferation which can result in store-depletion of Ca2+. Up regulation of genes which contribute to store operated channel (SOC) activity may plausibly be necessary for these processes to take place efficiently. TRPC proteins constitute a family of conserved Ca2+-permeable channels that have been shown to contribute to SOC activity.


RESULTS
In breast cancer biopsy tissues, TRPC3 and TRPC6 were the predominant TRPC genes expressed with TRPC3 and TRPC6 being significantly up regulated compared to normal breast tissue. In the lowly metastatic breast cancer cell line MCF-7, TRPC6 was the chief TRPC gene expressed while in the highly metastatic breast cancer cell line MDA-MB-231 both TRPC3 and TRPC6 were the predominant TRPC genes expressed. Western blotting, immunoconfocal analysis and immunoprecipitation experiments confirmed that the MDA-MB-231 cell line expressed both TRPC3 and TRPC6 protein with the majority of protein being intracellular. TRPC3 and TRPC6 were found to be in an immunoprecipitatble complex and co-localize within the cell. To demonstrate the potential of targeting TRP channels in breast cancer, hyperforin reportably a specific activator of TRPC6 significantly reduced the growth and viability of the breast cancer cell lines but had no effect on the non-cancerous breast cell line. Silencing of TRPC6 in MDA-MB-231 cells resulted in a significant reduction in cell growth but not viability.


CONCLUSIONS
TRPC channels may be potential future targets for breast cancer diagnosis and therapy and deserve further investigation to evaluate their role in cancer cell physiology.
Aydar
Ebru
E
London Metropolitan University, Institute for Health Research and Policy, 166-220 Holloway Road, London, N7 8DB, UK. e.aydar@londonmet.ac.uk
Yeo
Syn
S
Djamgoz
Mustafa
M
Palmer
Christopher
C
Lancet Oncol. 2008 Aug;9(8):730-56
18639491
J Biol Chem. 2005 Apr 1;280(13):12908-16
15623527
Nat Rev Cancer. 2007 Jul;7(7):519-30
17585332
Cell Prolif. 2008 Feb;41(1):98-121
18211288
Biochim Biophys Acta. 2007 Aug;1772(8):937-46
17616360
BMC Cancer. 2008 May 02;8:125
18452628
Nucleic Acids Res. 2001 May 1;29(9):e45
11328886
Cancer Res. 2006 Feb 15;66(4):2038-47
16489003
Cancer Res. 2008 Mar 15;68(6):1611-3
18339837
Cancer Lett. 2009 Jan 18;273(2):177-93
18632203
FASEB J. 2007 Dec;21(14):4101-11
17666455
Biol Reprod. 2002 Sep;67(3):988-94
12193412
J Membr Biol. 2006;211(2):127-37
17041782
Nat Rev Neurosci. 2007 Jul;8(7):510-21
17585304
Eur Biophys J. 2008 Apr;37(4):359-68
17879092
Mol Cancer Ther. 2008 Feb;7(2):271-9
18245667
Cancer Res. 2004 Sep 1;64(17):6225-32
15342408
Cancer Metastasis Rev. 2006 Sep;25(3):493-500
17111226
Cell Death Differ. 2007 Jul;14(7):1295-304
17479110
Hepatology. 2008 Jun;47(6):2068-77
18506892
Nucleic Acids Res. 2003 Jul 15;31(14):e73
12853650
Annu Rev Biochem. 2007;76:387-417
17579562